QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

SLDB

QT85Solid Biosciences Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
8.33
+1.02+13.95%
OverviewShort InterestFilings
SLDBQT85Solid Biosciences Inc.·NASDAQ
OverviewShort InterestFilings
8.33+13.95%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-11.56
Insider Own-
Shs Outstand98.45M
Perf Week15.37%
Market Cap569.52MForward P/E-EPS next Y-1.93Insider Trans1.34%Shs Float-Perf Month37.01%
Enterprise Value292.45MPEG-EPS next Q-0.43Inst Own-Short Float-Perf Quarter16.99%
Income-136059179.00P/S0.00EPS this Y83.27%Inst Trans-Short Ratio-Perf Half Y43.13%
Sales-P/B2.15EPS next Y0.23%ROA-45.35%Short Interest-Perf YTD47.70%
Book/sh3.80P/C-EPS next 5Y-ROE-74.45%52W High8.87 -6.09%Perf Year80.69%
Cash/sh3.87P/FCF-EPS past 3/5Y-ROIC-49.76%52W Low3.79 119.79%Perf 3Y-
Dividend Est.-EV/EBITDA-1.54Sales past 3/5Y-Gross Margin0.00%Volatility4.68% 4.38%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM37.25%Oper. Margin0.00%ATR (14)0.53Perf 10Y-
Dividend Ex-Date-Quick Ratio13.10Sales Y/Y TTM-Profit Margin0.00%RSI (14)64.16Recom2.00
Dividend Gr. 3/5Y-Current Ratio13.10EPS Q/Q11.86%SMA2018.99%Beta2.21Target Price17.00
Payout0.00%Debt/Eq0.06Sales Q/Q-SMA5013.26%Rel Volume9.83Prev Close7.31
Employees100LT Debt/Eq0.11EarningsAug 11SMA20032.68%Avg Volume1.45MPrice8.33
IPO DateJan 26, 2018Option/ShortYes / YesEPS/Sales Surpr.-30.00% -Net Debt/EBITDA1.46Volume14,271,499Change13.95%
Analyst Ratings
DateActionAnalystRatingTarget
May-13-26ReiteratedWedbushOutperform$16
May-13-26ReiteratedPiper SandlerOverweight$20 → $18
Dec-04-25InitiatedNeedhamBuy$16
Nov-04-25ReiteratedBarclaysOverweight$18 → $9.00
Jul-21-25ReiteratedCantor Fitzgerald$16
Jul-15-24UpgradeJP MorganNeutral → Overweight
Jun-24-24UpgradeLeerink PartnersMarket Perform → Outperform$12
May-31-24ReiteratedPiper SandlerOverweight$20
May-16-24ReiteratedBarclaysOverweight$18
Mar-14-24UpgradePiper SandlerNeutral → Overweight
Latest News
Jun-17-26
Jun-17-2608:03AM
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1500
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A022
Gross Profit15-2-2
Selling, General and Administrative Excl. Other283933
Research and Development7214096
Other Operating Expense3-1-2
Operating Income-87-179-130
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-2-5-5
Net Income Before Taxes-87-174-125
Income Taxes
000
Consolidated Net Income-87-174-125
Net Income From Continuing Operations-87-174-125
Net Income-87-174-125
EPS (Recurring)-11.60-1.99-3.06
EPS (Basic, Before Extraordinaries)-11.60-1.99-3.06
EPS (Diluted)-11.56-1.99-3.06
EBITDA-83-173-122
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
4.44——
Gross Margin100.00——
Operating Margin-580.00——
Net Margin-580.00——
Shares Outstanding88841
Market Capitalization67496—
Operating Lease Expense
———
Insider Trading Volume
$9.68$8.94$8.21$7.47$6.73● Close Price0.00M0.62M1.25M1.87M2.50MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
SMITH IAN FDirectorApr 02 '26Option Exercise0.006,8820134,705Apr 02 12:00 AM
Tan KevinCFO & TreasurerFeb 18 '26Sale5.825,40431,46999,422Feb 18 12:00 AM
Herzich PaulChief Technology OfficerFeb 18 '26Sale5.823,61621,05772,638Feb 18 12:00 AM
Howton David TChief Operating OfficerFeb 18 '26Sale5.827,46943,494105,077Feb 18 12:00 AM
Brooks GabrielChief Medical OfficerFeb 18 '26Sale5.820089,466Feb 18 12:00 AM
Ganot IlanDirectorFeb 18 '26Sale5.822,65815,47827,474Feb 18 12:00 AM
Cumbo AlexanderPresident and CEOFeb 18 '26Sale5.8216,64496,923235,405Feb 18 12:00 AM
Hanrahan JessieChief Regulatory OfficerFeb 18 '26Sale5.824,13424,07474,318Feb 18 12:00 AM
Howton David TChief Operating OfficerFeb 13 '26Option Exercise0.0029,3740112,546Feb 18 12:00 AM
Cumbo AlexanderPresident and CEOFeb 13 '26Option Exercise0.0060,0620252,049Feb 18 12:00 AM
Hanrahan JessieChief Regulatory OfficerFeb 13 '26Option Exercise0.0016,250078,452Feb 18 12:00 AM
Ganot IlanDirectorFeb 13 '26Option Exercise0.009,722030,132Feb 18 12:00 AM
Herzich PaulChief Technology OfficerFeb 13 '26Option Exercise0.0014,374076,254Feb 18 12:00 AM
Brooks GabrielChief Medical OfficerFeb 13 '26Option Exercise0.0021,874095,029Feb 18 12:00 AM
Tan KevinCFO & TreasurerFeb 13 '26Option Exercise0.0021,2500104,826Feb 18 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR